Skip to main content
Perfusate for optimized gene delivery to donor organs undergoing ex vivo machine perfusion

Perfusate for optimized gene delivery to donor organs undergoing ex vivo machine perfusion

Unmet Need Effective gene delivery is notoriously difficult to achieve to an entire target organ. Gene therapies have traditionally been administered intravascularly, requiring high vector doses to attain therapeutic levels of expression. Because of this…

Read More

Targeted delivery of gene therapy for cardiac reprogramming with enhanced efficacy

Targeted delivery of gene therapy for cardiac reprogramming with enhanced efficacy

Unmet Need Cardiac injury results in irreversible and permanent loss of cardiomyocytes, leading to heart failure with ~40% mortality within 4 years from diagnosis. It has been shown that directly reprogramming scar fibroblasts into new…

Read More

Anti-cancer therapeutic for the induction of apoptosis in solid tumors via TRAIL receptors

Anti-cancer therapeutic for the induction of apoptosis in solid tumors via TRAIL receptors

Unmet Need Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL, CD253) acts as an activator of apoptosis in many tumor cells, while remaining innocuous to normal cells. Both membrane-bound and soluble forms of TRAIL can trigger apoptosis…

Read More

Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy

Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy

Unmet Need In the United States alone, over 1.8 million new patients were diagnosed with cancer in 2021, and over 600,000 patients died from the disease. Cytostatic nucleotides, such as gemcitabine and 5-fluorouracil, have been…

Read More

A class of biodegradable stealth polymers to improve drug delivery

A class of biodegradable stealth polymers to improve drug delivery

Unmet Need Delivery of drugs or therapeutics such as small molecules, peptides, and proteins, in their native form, is limited by their poor stability, low solubility, and short in vivo circulation. These challenges in drug…

Read More

Increasing the half-life of therapeutic proteins and peptides using elastomeric-like polypeptides with environmental sensitivity

Increasing the half-life of therapeutic proteins and peptides using elastomeric-like polypeptides with environmental sensitivity

Value Proposition Since insulin was used as the first therapeutic protein in a clinical setting, the field of protein therapeutics has rapidly expanded. From 2014-2018, therapeutic proteins had the highest compound annual growth rate of…

Read More

Unstructured non-repetitive polypeptides as a tool for imparting temperature-dependent physical properties to protein fusions

Unstructured non-repetitive polypeptides as a tool for imparting temperature-dependent physical properties to protein fusions

Value Proposition Proteins can be useful therapeutic agents when engineered for specificity and selectivity for a clinical target. Their complexity, versatility, tolerability, and diversity often make them superior alternatives to small molecule drugs, and the…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us